ScholarIQanswers from OpenAlex
Universidad Autónoma de la Ciudad de México
InstitutionResearch output, impact & collaborations
Universidad Autónoma de la Ciudad de México is a institution indexed in ScholarIQ from OpenAlex.
What is known about Universidad Autónoma de la Ciudad de México?
ScholarIQrecord summary
Universidad Autónoma de la Ciudad de México is a research organisation in Mexico City, MX. OpenAlex records 11,732 works and 145,760 citations for it. 4,806 researchers list it as their most recent affiliation.
How many works does Universidad Autónoma de la Ciudad de México have?
ScholarIQindexed works
Universidad Autónoma de la Ciudad de México has 11,732 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Universidad Autónoma de la Ciudad de México have?
ScholarIQcitation count
Universidad Autónoma de la Ciudad de México has 145,760 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Universidad Autónoma de la Ciudad de México?
ScholarIQresearcher count
Universidad Autónoma de la Ciudad de México has 4,806 researchers in the ScholarIQ index.
What is the average h-index at Universidad Autónoma de la Ciudad de México?
ScholarIQavg h-index
Universidad Autónoma de la Ciudad de México has an average h-index of 72.5 in OpenAlex.
What is the ROR of Universidad Autónoma de la Ciudad de México?
ScholarIQror
The ROR for Universidad Autónoma de la Ciudad de México is on the source record.
What is the OpenAlex record for Universidad Autónoma de la Ciudad de México?
ScholarIQopenalex
The OpenAlex for Universidad Autónoma de la Ciudad de México is on the source record.
What is the Wikidata of Universidad Autónoma de la Ciudad de México?
ScholarIQwikidata
The Wikidata for Universidad Autónoma de la Ciudad de México is on the source record.
Who are the most-cited researchers behind Universidad Autónoma de la Ciudad de México?
ScholarIQtop researchers by citations
What are the most-cited papers on Universidad Autónoma de la Ciudad de México?
ScholarIQmost cited works
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S Smolen, Robert Landewé, Johannes Bijlsma, Gerd Burmester, Katerina Chatzidionysiou, Maxime Dougados, J. Nam, Sofía Ramiro, Marieke Voshaar, Ronald van Vollenhoven, Daniel Aletaha, Martin Aringer, Maarten Boers, Christopher D. Buckley, Frank Buttgereit, Vivian P. Bykerk, Mario Cardiel, Bernard Combe, Maurizio Cutolo, Yvonne van Eijk‐Hustings, Paul Emery, Axel Finckh, Cem Gabay, Juan J. Gómez‐Reino, Laure Gossec, J.-E. Gottenberg, Johanna M W Hazes, T. Huizinga, Meghna Jani, Д. Е. Каратеев, Marios Kouloumas, Tore Kvien, Zhanguo Li, Xavier Mariette, Iain B. McInnes, Eduardo Mysler, Peter Nash, Karel Pavelká, Gyula Poór, Christophe Richez, Piet L. C. M. van Riel, Andrea Rubbert‐Roth, Kenneth G. Saag, José António Pereira da Silva, Tanja Stamm, Tsutomu Takeuchi, René Westhovens, Maarten de Wit, Désirée van der Heijde
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Josef S Smolen, Robert Landewé, J. W. J. Bijlsma, Gerd R Burmester, Maxime Dougados, Andreas Kerschbaumer, Iain B. McInnes, Alexandre Sepriano, Ronald van Vollenhoven, Maarten de Wit, Daniel Aletaha, Martin Aringer, Johan Askling, Alejandro Balsa, Maarten Boers, Alfons A den Broeder, Maya H Buch, Frank Buttgereit, Roberto Caporali, Myrna Cardiel, Diederik De Cock, Cătălin Codreanu, Maurizio Cutolo, Christopher J Edwards, Yvonne van Eijk‐Hustings, Paul Emery, Axel Finckh, Laure Gossec, Jacques‐Eric Gottenberg, Merete Lund Hetland, T. Huizinga, Marios Koloumas, Zhanguo Li, Xavier Mariette, Ulf Müller‐Ladner, Eduardo Mysler, José António Pereira da Silva, Gyula Poór, Janet Pope, Andrea Rubbert‐Roth, Adeline Ruyssen‐Witrand, Kenneth G. Saag, Anja Strangfeld, Tsutomu Takeuchi, Marieke Voshaar, René Westhovens, Désirée van der Heijde
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
Josef S Smolen, Robert Landewé, Sytske Anne Bergstra, Andreas Kerschbaumer, Alexandre Sepriano, Daniel Aletaha, Roberto Caporali, Christopher J Edwards, Kimme L Hyrich, Janet Pope, Savia de Souza, Tanja Stamm, Tsutomu Takeuchi, Patrick Verschueren, Kevin Winthrop, Alejandro Balsa, Joan M. Bathon, Maya H Buch, Gerd R Burmester, Frank Buttgereit, Myrna Cardiel, Katerina Chatzidionysiou, Cătălin Codreanu, Maurizio Cutolo, Alfons A den Broeder, Khadija El Aoufy, Axel Finckh, João Eurico Fonseca, Jacques‐Eric Gottenberg, Espen A. Haavardsholm, Annamaria Iagnocco, Kim Lauper, Zhanguo Li, Iain B. McInnes, Eduardo Mysler, Peter Nash, Gyula Poór, Gorica Ristić, Felice Rivellese, Andrea Rubbert‐Roth, Hendrik Schulze‐Koops, Nikolay Stoilov, Anja Strangfeld, Annette H M van der Helm–van Mil, Elsa van Duuren, T. P. M. Vliet Vlieland, René Westhovens, Désirée van der Heijde
Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis
Gerald B. Appel, Gabriel Contreras, Mary Anne Dooley, Ellen M. Ginzler, David Isenberg, David Jayne, LI Leishi, Eduardo Mysler, Jorge Sa[Combining Acute Accent]nchez-Guerrero, Neil Solomons, David Wofsy
How much of the research on Universidad Autónoma de la Ciudad de México is open access?
ScholarIQopen access share
100%OPEN ACCESS